Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1952 1
1953 5
1957 2
1958 2
1959 1
1960 1
1961 6
1962 6
1963 17
1964 20
1965 19
1966 18
1967 30
1968 29
1969 21
1970 24
1971 28
1972 21
1973 25
1974 21
1975 20
1976 24
1977 26
1978 32
1979 30
1980 40
1981 45
1982 58
1983 83
1984 79
1985 69
1986 66
1987 66
1988 63
1989 80
1990 70
1991 105
1992 107
1993 96
1994 89
1995 110
1996 138
1997 136
1998 132
1999 115
2000 176
2001 151
2002 153
2003 151
2004 130
2005 168
2006 204
2007 150
2008 167
2009 155
2010 158
2011 194
2012 208
2013 232
2014 193
2015 233
2016 215
2017 224
2018 238
2019 208
2020 266
2021 295
2022 287
2023 234
2024 261
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,683 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Finn RS, et al. Among authors: ikeda m. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.
ZBP1 Protects Against mtDNA-Induced Myocardial Inflammation in Failing Hearts.
Enzan N, Matsushima S, Ikeda S, Okabe K, Ishikita A, Yamamoto T, Sada M, Miyake R, Tsutsui Y, Nishimura R, Toyohara T, Ikeda Y, Shojima Y, Miyamoto HD, Tadokoro T, Ikeda M, Abe K, Ide T, Kinugawa S, Tsutsui H. Enzan N, et al. Among authors: ikeda m. Circ Res. 2023 Apr 28;132(9):1110-1126. doi: 10.1161/CIRCRESAHA.122.322227. Epub 2023 Mar 28. Circ Res. 2023. PMID: 36974722 Free PMC article.
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Nakachi K, et al. Among authors: ikeda m. Lancet. 2023 Jan 21;401(10372):195-203. doi: 10.1016/S0140-6736(22)02038-4. Lancet. 2023. PMID: 36681415 Clinical Trial.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Among authors: ikeda m. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Lee MA, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, Żotkiewicz M, Kurland JF, Cohen G, Valle JW. Oh DY, et al. Among authors: ikeda m. Future Oncol. 2023 Nov;19(34):2277-2289. doi: 10.2217/fon-2023-0468. Epub 2023 Sep 25. Future Oncol. 2023. PMID: 37746835 Free article. Review.
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Kudo M, et al. Among authors: ikeda m. Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4. Gut. 2020. PMID: 31801872 Free PMC article. Clinical Trial.
Iron Overload via Heme Degradation in the Endoplasmic Reticulum Triggers Ferroptosis in Myocardial Ischemia-Reperfusion Injury.
Miyamoto HD, Ikeda M, Ide T, Tadokoro T, Furusawa S, Abe K, Ishimaru K, Enzan N, Sada M, Yamamoto T, Matsushima S, Koumura T, Yamada KI, Imai H, Tsutsui H. Miyamoto HD, et al. Among authors: ikeda m. JACC Basic Transl Sci. 2022 Jul 27;7(8):800-819. doi: 10.1016/j.jacbts.2022.03.012. eCollection 2022 Aug. JACC Basic Transl Sci. 2022. PMID: 36061338 Free PMC article.
[Hirotaka Tanabe].
Hashimoto M, Fukuhara R, Ikeda M. Hashimoto M, et al. Among authors: ikeda m. Brain Nerve. 2014 Nov;66(11):1355-62. doi: 10.11477/mf.1416200040. Brain Nerve. 2014. PMID: 25407070 Japanese.
6,683 results